Masupirdine is an investigational new drug that is being evaluated for the treatment of agitation in Alzheimer's dementia.[1] It is a selective 5-HT6 receptor antagonist.[2]

See also

References

  1. "Masupirdine - Suven Life Sciences". AdisInsight. Springer Nature Switzerland AG.
  2. Nirogi R, Jayarajan P, Shinde A, Mohammed AR, Grandhi VR, Benade V, et al. (February 2023). "Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders". Biomolecules. 13 (2): 309. doi:10.3390/biom13020309. PMC 9953539. PMID 36830678.